FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2132912591> ?p ?o ?g. }

• W2132912591 endingPage "4335" @default.
• W2132912591 startingPage "4326" @default.
• W2132912591 abstract "Constitutive activation of the FLT3 receptor tyrosine kinase, either by internal tandem duplication (ITD) of the juxtamembrane region or by point mutations in the second tyrosine kinase domain (TKD), has been described in patients with acute myelogenous leukemia (AML). We analyzed the prevalence and the potential prognostic impact of FLT3 mutations in 979 AML patients. Results were correlated with cytogenetic data and the clinical response. FLT3-ITD mutations were found in 20.4% and FLT3-TKD mutations in 7.7% of the patients. Each mutation was associated with similar clinical characteristics and was more prevalent in patients with normal karyotype. Significantly more FLT3 aberrations were found in patients with FAB M5, and fewer were found in patients with FAB M2 and M6. Although less frequent in patients with cytogenetic aberrations, FLT3-ITDs were found in 13 of 42 patients with t(15;17) and in 9 of 10 patients with t(6;9). The prevalence of the ITD allele on the DNA level was heterogeneous, ranging from faint mutant bands in some patients to predominant mutant bands in others. Based on quantitative analysis, the mutant–wild-type (wt) ratio ranged from 0.03 to 32.56 (median, 0.78). Patients with a high mutant/wt ratio (ie, greater than 0.78) had significantly shorter overall and disease-free survival, whereas survival in patients with ratios below 0.78 did not differ from those without FLT3 aberrations. Multivariate analysis confirmed a high mutant/wt ratio to be a strong independent prognostic factor. Taken together, these data confirm that FLT mutations represent a common alteration in adult AML. Constitutive activation may be associated with monocytoid differentiation. A high mutant/wt ratio in ITD-positive patients appears to have a major impact on the prognostic relevance." @default.
• W2132912591 created "2016-06-24" @default.
• W2132912591 creator A5006122560 @default.
• W2132912591 creator A5017002895 @default.
• W2132912591 creator A5018356664 @default.
• W2132912591 creator A5025390295 @default.
• W2132912591 creator A5026849709 @default.
• W2132912591 creator A5034434819 @default.
• W2132912591 creator A5042618484 @default.
• W2132912591 creator A5043264175 @default.
• W2132912591 creator A5045850647 @default.
• W2132912591 creator A5048469868 @default.
• W2132912591 creator A5063053133 @default.
• W2132912591 creator A5079124367 @default.
• W2132912591 date "2002-06-15" @default.
• W2132912591 modified "2023-10-16" @default.
• W2132912591 title "Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis" @default.
• W2132912591 cites W148052780 @default.
• W2132912591 cites W1486112083 @default.
• W2132912591 cites W1492609361 @default.
• W2132912591 cites W1515269506 @default.
• W2132912591 cites W1534965621 @default.
• W2132912591 cites W1542395305 @default.
• W2132912591 cites W1544851750 @default.
• W2132912591 cites W1953611650 @default.
• W2132912591 cites W1965754215 @default.
• W2132912591 cites W1968306285 @default.
• W2132912591 cites W1971056717 @default.
• W2132912591 cites W1978469902 @default.
• W2132912591 cites W1985285007 @default.
• W2132912591 cites W1987076025 @default.
• W2132912591 cites W2004477791 @default.
• W2132912591 cites W2021236910 @default.
• W2132912591 cites W2022708678 @default.
• W2132912591 cites W2027077464 @default.
• W2132912591 cites W2032235066 @default.
• W2132912591 cites W2034820298 @default.
• W2132912591 cites W2036280246 @default.
• W2132912591 cites W2038950074 @default.
• W2132912591 cites W2047626730 @default.
• W2132912591 cites W2050502992 @default.
• W2132912591 cites W2051864256 @default.
• W2132912591 cites W2060159346 @default.
• W2132912591 cites W2071432029 @default.
• W2132912591 cites W2086404440 @default.
• W2132912591 cites W2091910297 @default.
• W2132912591 cites W2099879752 @default.
• W2132912591 cites W2128252502 @default.
• W2132912591 cites W2130864403 @default.
• W2132912591 cites W2253167439 @default.
• W2132912591 cites W2280729002 @default.
• W2132912591 cites W2317475893 @default.
• W2132912591 cites W2321946412 @default.
• W2132912591 cites W256420660 @default.
• W2132912591 cites W4293241248 @default.
• W2132912591 cites W4294216491 @default.
• W2132912591 cites W4312790597 @default.
• W2132912591 cites W4385970358 @default.
• W2132912591 doi "https://doi.org/10.1182/blood.v99.12.4326" @default.
• W2132912591 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12036858" @default.
• W2132912591 hasPublicationYear "2002" @default.
• W2132912591 type Work @default.
• W2132912591 sameAs 2132912591 @default.
• W2132912591 citedByCount "1590" @default.
• W2132912591 countsByYear W21329125912012 @default.
• W2132912591 countsByYear W21329125912013 @default.
• W2132912591 countsByYear W21329125912014 @default.
• W2132912591 countsByYear W21329125912015 @default.
• W2132912591 countsByYear W21329125912016 @default.
• W2132912591 countsByYear W21329125912017 @default.
• W2132912591 countsByYear W21329125912018 @default.
• W2132912591 countsByYear W21329125912019 @default.
• W2132912591 countsByYear W21329125912020 @default.
• W2132912591 countsByYear W21329125912021 @default.
• W2132912591 countsByYear W21329125912022 @default.
• W2132912591 countsByYear W21329125912023 @default.
• W2132912591 crossrefType "journal-article" @default.
• W2132912591 hasAuthorship W2132912591A5006122560 @default.
• W2132912591 hasAuthorship W2132912591A5017002895 @default.
• W2132912591 hasAuthorship W2132912591A5018356664 @default.
• W2132912591 hasAuthorship W2132912591A5025390295 @default.
• W2132912591 hasAuthorship W2132912591A5026849709 @default.
• W2132912591 hasAuthorship W2132912591A5034434819 @default.
• W2132912591 hasAuthorship W2132912591A5042618484 @default.
• W2132912591 hasAuthorship W2132912591A5043264175 @default.
• W2132912591 hasAuthorship W2132912591A5045850647 @default.
• W2132912591 hasAuthorship W2132912591A5048469868 @default.
• W2132912591 hasAuthorship W2132912591A5063053133 @default.
• W2132912591 hasAuthorship W2132912591A5079124367 @default.
• W2132912591 hasBestOaLocation W21329125911 @default.
• W2132912591 hasConcept C104317684 @default.
• W2132912591 hasConcept C10515644 @default.
• W2132912591 hasConcept C126322002 @default.
• W2132912591 hasConcept C143065580 @default.
• W2132912591 hasConcept C143998085 @default.
• W2132912591 hasConcept C163565370 @default.
• W2132912591 hasConcept C176944494 @default.
• W2132912591 hasConcept C180754005 @default.

• next